Carmen Kahatt

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 462 citations

Medicine, Oncology, Pharmacology +9

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Céline Berthon, Emmanuel Raffoux, Xavier Thomas et al. · The Lancet Haematology · 2016 · 431 citations

Medicine, Hematology, Pharmacology +7

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson et al. · The Lancet Haematology · 2016 · 428 citations

Medicine, Pharmacokinetics, Pharmacology +13

Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients

Alejandro Yovine, M. Riofrio, Jean‐Yves Blay et al. · Journal of Clinical Oncology · 2004 · 310 citations

Medicine, Oncology, Pharmacokinetics +13

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro et al. · The Lancet Respiratory Medicine · 2022 · 120 citations · Full text

Medicine, Oncology, Pharmacology +11